Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%

Joseph M Blondeau,1 Howard M Proskin,2 Christine M Sanfilippo,3 Heleen H DeCory3 1Clinical Microbiology, Royal University Hospital, Saskatoon, SK, Canada; 2Howard M. Proskin & Associates, Rochester, NY, USA; 3Pharmaceutical Medical Affairs, Bausch + Lomb, Rochester, NY, USACorrespondence: Heleen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Blondeau JM, Proskin HM, Sanfilippo CM, DeCory HH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	pediatric conjunctivitis polybacterial besifloxacin minimum inhibitory concentration Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/38f55f48aa2548318fb3802e58e6973b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:38f55f48aa2548318fb3802e58e6973b
record_format	dspace
spelling	oai:doaj.org-article:38f55f48aa2548318fb3802e58e6973b2021-12-02T18:11:23ZCharacterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%1177-5483https://doaj.org/article/38f55f48aa2548318fb3802e58e6973b2021-11-01T00:00:00Zhttps://www.dovepress.com/characterization-of-polybacterial-versus-monobacterial-conjunctivitis--peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Joseph M Blondeau,1 Howard M Proskin,2 Christine M Sanfilippo,3 Heleen H DeCory3 1Clinical Microbiology, Royal University Hospital, Saskatoon, SK, Canada; 2Howard M. Proskin & Associates, Rochester, NY, USA; 3Pharmaceutical Medical Affairs, Bausch + Lomb, Rochester, NY, USACorrespondence: Heleen H DeCoryPharmaceutical Medical Affairs, 1400 North Goodman Street, Rochester, NY, 14609, USATel +1 585 338-8161Email Heleen.DeCory@bausch.comIntroduction: The choice of empiric therapy for bacterial conjunctivitis should be guided by an awareness of typical causative pathogen distributions. Bacterial conjunctivitis can be polybacterial, although pediatric-specific data are lacking.Methods: This was a post-hoc analysis of data in pediatric subjects (1– 17 years) from five bacterial conjunctivitis trials evaluating besifloxacin ophthalmic solution 0.6%.Results: Of the 730 pediatric subjects with culture-confirmed conjunctivitis, nearly one-fourth (23.6%) had polybacterial infections and three-fourths (76.4%) had monobacterial infections at baseline. In both polybacterial and monobacterial infections, the most prevalent organisms were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus mitis/S. mitis group. In polybacterial versus monobacterial infections, S. mitis/S. mitis group (8.7% vs 4.3%; P=0.032) and Moraxella catarrhalis (4.7% vs 0.5%; P< 0.001) were identified more frequently, whereas S. pneumoniae (14.0% vs 28.1%; P< 0.001) was identified less frequently, as the dominant infecting species. MICs for individual species were similar for tested antibiotics regardless of polybacterial or monobacterial infection, except Staphylococcus epidermidis for which fluoroquinolone MICs were ≥ 3 dilutions higher for isolates of this species sourced from polybacterial compared to monobacterial infections. Treatment with besifloxacin resulted in microbial eradication in 79.1% of polybacterial and 92.3% of monobacterial infections (P≤ 0.005 vs vehicle).Discussion: One in four pediatric bacterial conjunctivitis infections is polybacterial, highlighting the need for a broad-spectrum antibiotic when choosing empiric therapy.Keywords: pediatric, conjunctivitis, polybacterial, besifloxacin, minimum inhibitory concentrationBlondeau JMProskin HMSanfilippo CMDeCory HHDove Medical Pressarticlepediatricconjunctivitispolybacterialbesifloxacinminimum inhibitory concentrationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 4419-4430 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pediatric conjunctivitis polybacterial besifloxacin minimum inhibitory concentration Ophthalmology RE1-994
spellingShingle	pediatric conjunctivitis polybacterial besifloxacin minimum inhibitory concentration Ophthalmology RE1-994 Blondeau JM Proskin HM Sanfilippo CM DeCory HH Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
description	Joseph M Blondeau,1 Howard M Proskin,2 Christine M Sanfilippo,3 Heleen H DeCory3 1Clinical Microbiology, Royal University Hospital, Saskatoon, SK, Canada; 2Howard M. Proskin & Associates, Rochester, NY, USA; 3Pharmaceutical Medical Affairs, Bausch + Lomb, Rochester, NY, USACorrespondence: Heleen H DeCoryPharmaceutical Medical Affairs, 1400 North Goodman Street, Rochester, NY, 14609, USATel +1 585 338-8161Email Heleen.DeCory@bausch.comIntroduction: The choice of empiric therapy for bacterial conjunctivitis should be guided by an awareness of typical causative pathogen distributions. Bacterial conjunctivitis can be polybacterial, although pediatric-specific data are lacking.Methods: This was a post-hoc analysis of data in pediatric subjects (1– 17 years) from five bacterial conjunctivitis trials evaluating besifloxacin ophthalmic solution 0.6%.Results: Of the 730 pediatric subjects with culture-confirmed conjunctivitis, nearly one-fourth (23.6%) had polybacterial infections and three-fourths (76.4%) had monobacterial infections at baseline. In both polybacterial and monobacterial infections, the most prevalent organisms were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus mitis/S. mitis group. In polybacterial versus monobacterial infections, S. mitis/S. mitis group (8.7% vs 4.3%; P=0.032) and Moraxella catarrhalis (4.7% vs 0.5%; P< 0.001) were identified more frequently, whereas S. pneumoniae (14.0% vs 28.1%; P< 0.001) was identified less frequently, as the dominant infecting species. MICs for individual species were similar for tested antibiotics regardless of polybacterial or monobacterial infection, except Staphylococcus epidermidis for which fluoroquinolone MICs were ≥ 3 dilutions higher for isolates of this species sourced from polybacterial compared to monobacterial infections. Treatment with besifloxacin resulted in microbial eradication in 79.1% of polybacterial and 92.3% of monobacterial infections (P≤ 0.005 vs vehicle).Discussion: One in four pediatric bacterial conjunctivitis infections is polybacterial, highlighting the need for a broad-spectrum antibiotic when choosing empiric therapy.Keywords: pediatric, conjunctivitis, polybacterial, besifloxacin, minimum inhibitory concentration
format	article
author	Blondeau JM Proskin HM Sanfilippo CM DeCory HH
author_facet	Blondeau JM Proskin HM Sanfilippo CM DeCory HH
author_sort	Blondeau JM
title	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
title_short	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
title_full	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
title_fullStr	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
title_full_unstemmed	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
title_sort	characterization of polybacterial versus monobacterial conjunctivitis infections in pediatric subjects across multiple studies and microbiological outcomes with besifloxacin ophthalmic suspension 0.6%
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/38f55f48aa2548318fb3802e58e6973b
work_keys_str_mv	AT blondeaujm characterizationofpolybacterialversusmonobacterialconjunctivitisinfectionsinpediatricsubjectsacrossmultiplestudiesandmicrobiologicaloutcomeswithbesifloxacinophthalmicsuspension06 AT proskinhm characterizationofpolybacterialversusmonobacterialconjunctivitisinfectionsinpediatricsubjectsacrossmultiplestudiesandmicrobiologicaloutcomeswithbesifloxacinophthalmicsuspension06 AT sanfilippocm characterizationofpolybacterialversusmonobacterialconjunctivitisinfectionsinpediatricsubjectsacrossmultiplestudiesandmicrobiologicaloutcomeswithbesifloxacinophthalmicsuspension06 AT decoryhh characterizationofpolybacterialversusmonobacterialconjunctivitisinfectionsinpediatricsubjectsacrossmultiplestudiesandmicrobiologicaloutcomeswithbesifloxacinophthalmicsuspension06
_version_	1718378565018320896

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%

Ejemplares similares